Literature DB >> 25356020

Hepatitis B virus and hepatitis C virus dual infection.

Gaia Caccamo1, Francesca Saffioti1, Giovanni Raimondo1.   

Abstract

Hepatitis B virus (HBV) and hepatitis C virus (HCV) share common mode of transmission and both are able to induce a chronic infection. Dual HBV/HCV chronic coinfection is a fairly frequent occurrence, especially in high endemic areas and among individuals at high risk of parenterally transmitted infections. The intracellular interplay between HBV and HCV has not yet been sufficiently clarified, also due to the lack of a proper in vitro cellular model. Longitudinal evaluation of serum HBV DNA and HCV RNA amounts has revealed that complex virological profiles may be present in coinfected patients. Dual HBV/HCV infection has been associated to a severe course of the liver disease and to a high risk of developing hepatocellular carcinoma. Despite the clinical importance, solid evidence and clear guidelines for treatment of this special population are still lacking. This review summarizes the available data on the virological and clinical features as well as the therapeutic options of the dual HBV/HCV infection, and highlights the aspects that need to be better clarified.

Entities:  

Keywords:  Antiviral therapy; Chronic hepatitis; Cirrhosis; Hepatitis B virus/hepatitis C virus coinfection; Hepatocellular carcinoma; Viral interaction

Mesh:

Substances:

Year:  2014        PMID: 25356020      PMCID: PMC4209523          DOI: 10.3748/wjg.v20.i40.14559

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  112 in total

Review 1.  Hepatitis C virus infection.

Authors:  G M Lauer; B D Walker
Journal:  N Engl J Med       Date:  2001-07-05       Impact factor: 91.245

2.  Mechanisms for inhibition of hepatitis B virus gene expression and replication by hepatitis C virus core protein.

Authors:  Shiow-Yi Chen; Chih-Fei Kao; Chun-Ming Chen; Chwen-Ming Shih; Ming-Jen Hsu; Chi-Hong Chao; Shao-Hung Wang; Li-Ru You; Yan-Hwa Wu Lee
Journal:  J Biol Chem       Date:  2002-10-24       Impact factor: 5.157

3.  High doses of alpha-interferon are required in chronic hepatitis due to coinfection with hepatitis B virus and hepatitis C virus: long term results of a prospective randomized trial.

Authors:  E Villa; A Grottola; P Buttafoco; A Colantoni; A Bagni; I Ferretti; C Cremonini; H Bertani; F Manenti
Journal:  Am J Gastroenterol       Date:  2001-10       Impact factor: 10.864

4.  Influence of hepatitis C virus on the profiles of patients with chronic hepatitis B virus infection.

Authors:  C Y Dai; M L Yu; W L Chuang; Z Y Lin; S C Chen; M Y Hsieh; L Y Wang; J F Tsai; W Y Chang
Journal:  J Gastroenterol Hepatol       Date:  2001-06       Impact factor: 4.029

5.  Ribavirin and interferon is effective for hepatitis C virus clearance in hepatitis B and C dually infected patients.

Authors:  Chun-Jen Liu; Pei-Jer Chen; Ming-Yang Lai; Jia-Horng Kao; Yung-Ming Jeng; Ding-Shinn Chen
Journal:  Hepatology       Date:  2003-03       Impact factor: 17.425

6.  Suppression of hepatitis B virus enhancer 1 and 2 by hepatitis C virus core protein.

Authors:  Christian G Schüttler; Nicola Fiedler; Katja Schmidt; Reinald Repp; Wolfram H Gerlich; Stephan Schaefer
Journal:  J Hepatol       Date:  2002-12       Impact factor: 25.083

7.  Prevalence and significance of hepatitis C viremia in chronic active hepatitis B.

Authors:  J Crespo; J L Lozano; F de la Cruz; L Rodrigo; M Rodríguez; G San Miguel; E Artiñano; F Pons-Romero
Journal:  Am J Gastroenterol       Date:  1994-08       Impact factor: 10.864

Review 8.  Structural biology of hepatitis C virus.

Authors:  François Penin
Journal:  Clin Liver Dis       Date:  2003-02       Impact factor: 6.126

Review 9.  Occult hepatitis B.

Authors:  Michael Torbenson; David L Thomas
Journal:  Lancet Infect Dis       Date:  2002-08       Impact factor: 25.071

10.  Coinfection of hepatitis C virus in patients with chronic hepatitis B infection.

Authors:  S Sato; S Fujiyama; M Tanaka; K Yamasaki; I Kuramoto; S Kawano; T Sato; K Mizuno; S Nonaka
Journal:  J Hepatol       Date:  1994-08       Impact factor: 25.083

View more
  29 in total

Review 1.  Hepatitis B reactivation during or after direct acting antiviral therapy - implication for susceptible individuals.

Authors:  Jacinta A Holmes; Ming-Lung Yu; Raymond T Chung
Journal:  Expert Opin Drug Saf       Date:  2017-05-19       Impact factor: 4.250

2.  [Spontaneous remission of HCV infection after autologous stem cell transplantation in a 58-year-old man].

Authors:  L Reinhardt; H Eiffert; G Wulf; P Ströbel; S C B Bremer; A Amanzada; V Ellenrieder; A Neesse
Journal:  Internist (Berl)       Date:  2017-06       Impact factor: 0.743

3.  Management of Hepatitis B Virus Infection: 2018 Guidelines from the Canadian Association for the Study of Liver Disease and Association of Medical Microbiology and Infectious Disease Canada.

Authors:  Carla S Coffin; Scott K Fung; Fernando Alvarez; Curtis L Cooper; Karen E Doucette; Claire Fournier; Erin Kelly; Hin Hin Ko; Mang M Ma; Steven R Martin; Carla Osiowy; Alnoor Ramji; Edward Tam; Jean Pierre Villeneuve
Journal:  Can Liver J       Date:  2018-12-25

4.  Recommendations for the management of hepatitis C virus infection among people who inject drugs.

Authors:  Jason Grebely; Geert Robaeys; Philip Bruggmann; Alessio Aghemo; Markus Backmund; Julie Bruneau; Jude Byrne; Olav Dalgard; Jordan J Feld; Margaret Hellard; Matthew Hickman; Achim Kautz; Alain Litwin; Andrew R Lloyd; Stefan Mauss; Maria Prins; Tracy Swan; Martin Schaefer; Lynn E Taylor; Gregory J Dore
Journal:  Int J Drug Policy       Date:  2015-07-17

Review 5.  Natural History of Hepatitis C.

Authors:  Shilpa Lingala; Marc G Ghany
Journal:  Gastroenterol Clin North Am       Date:  2015-08-25       Impact factor: 3.806

Review 6.  INASL Position Statements on Prevention, Diagnosis and Management of Hepatitis B Virus Infection in India: The Andaman Statements.

Authors:  Anil Arora; Shivaram P Singh; Ashish Kumar; Vivek A Saraswat; Rakesh Aggarwal; Manisha Bangar; Pradip Bhaumik; Harshad Devarbhavi; Radha K Dhiman; Vinod K Dixit; Ashish Goel; Bhabadev Goswami; Dharmesh Kapoor; Kaushal Madan; Jimmy Narayan; Sandeep Nijhawan; Gaurav Pandey; Ramesh R Rai; Manoj K Sahu; Neeraj Saraf; Thrivikrama Shenoy; Varghese Thomas; Manav Wadhawan
Journal:  J Clin Exp Hepatol       Date:  2017-12-16

7.  Replication Inhibition of Hepatitis B Virus and Hepatitis C Virus in Co-Infected Patients in Chinese Population.

Authors:  Ge Yu; Xiumei Chi; Ruihong Wu; Xiaomei Wang; Xiuzhu Gao; Fei Kong; Xiangwei Feng; Yuanda Gao; Xinxing Huang; Jinglan Jin; Yue Qi; Zhengkun Tu; Bing Sun; Jin Zhong; Yu Pan; Junqi Niu
Journal:  PLoS One       Date:  2015-09-30       Impact factor: 3.240

8.  Epidemiology of Chronic Hepatitis C Infections at a Tertiary Care Centre in Oman.

Authors:  Said A Al-Busafi; Halima Al-Shuaili; Heba Omar; Haifa Al-Zuhaibi; L Jeyaseelan; Khalid Al-Naamani
Journal:  Sultan Qaboos Univ Med J       Date:  2018-01-10

9.  Fast antibody responses by immuno-targeting and nanotechnology strategies versus HBsAg vaccine.

Authors:  Mahsa Rezaei; Seyed Nezamedin Hosseini; Ramazan Ali Khavari-Nejad; Farhood Najafi; Mehdi Mahdavi
Journal:  Iran J Basic Med Sci       Date:  2021-04       Impact factor: 2.699

10.  Do Blood-Borne Viruses Affect the Progression of Labor: A Hospital-Based Pilot Study.

Authors:  Amrita Gaurav; Dhriti Kapur; Neha Verma; Anupama Bahadur; Kavita Khoiwal; Anchal Agarwal; Om Kumari; Jaya Chaturwedi
Journal:  Cureus       Date:  2021-06-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.